We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Mallinckrodt to Sell Nuclear Imaging Business to IBA Molecular

By MedImaging International staff writers
Posted on 26 Aug 2016
Print article
Mallinckrodt plc (Dublin, Ireland) has entered into a definitive agreement to sell its nuclear imaging business to IBA Molecular (IBAM) (Sterling, VA, USA) for approximately USD 690 million.

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, while its nuclear imaging business includes diagnostic imaging products. The company is a global producer of the key medical isotope molybdenum-99, from which technetium-99m is derived for use in roughly 80% of all nuclear medicine procedures worldwide. IBAM is a global manufacturer and distributor of radiopharmaceutical products with a product portfolio and pipeline of diagnostic and therapeutic tracers, and is active in the PET and SPECT segments.

"Mallinckrodt's Nuclear Imaging operation has a long history going back 50 years, and has been a strong cash-generating business over time. Our team has made significant progress in driving profitability over the past few years," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. "But with our strategic priorities focused on enlarging our portfolio in the high-growth specialty pharmaceuticals space," Trudeau continued, "we believe the sale of our Nuclear Imaging portfolio to IBAM is the best solution for both the business itself and Mallinckrodt."

Renaud Dehareng, Chief Executive Officer of IBAM, said, "We are very excited about this acquisition. IBAM's and Mallinckrodt's Nuclear Imaging business' complementary footprint and capabilities will substantially broaden our ability to serve patients globally. We are very pleased to welcome our new colleagues to IBAM upon closing and look forward to working together in this next chapter of our company's development."

Related Links:
Mallinckrodt
IBA Molecular
New
Mobile X-Ray Machine
MARS 15 / 30
New
Medical Radiographic X-Ray Machine
TR30N HF
Wall Fixtures
MRI SERIES
New
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector

Print article

Channels

MRI

view channel
Image: An MRI scan can reveal a heart’s functional age (Photo courtesy of 123RF)

New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes

Heart disease remains one of the leading causes of death worldwide. Individuals with conditions such as diabetes or obesity often experience accelerated aging of their hearts, sometimes by decades.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.